Microbial Ecology in Health and Disease

Background/Aims: Mechanisms by which synbiotic treatment improves liver function in patients with cirrhosis are unknown. This study was performed to address this important issue. Patients and methods: Thirty cirrhotic patients were randomized to receive synbiotic or placebo preparations for 7 days. Viable faecal counts of Lactobacillus species, Child-Pugh class, plasma retention rate of indocyanine green (ICGR15), whole blood tumour necrosis factor alpha (TNF-a) mRNA and interleukin-6 (IL-6) mRNA, serum TNF-a, soluble TNF receptor (sTNFR)I, sTNFRII and IL-6 and plasma endotoxin levels were measured preand post-treatment. Results: Synbiotic treatment was associated with significantly increased faecal lactobacilli counts and significant improvements in ICGR15 and Child-Pugh class. Significant increases in whole blood TNF-a mRNA and IL-6 mRNA, along with serum levels of sTNFRI and sTNFRII, also occurred. TNF-a and IL-6 levels correlated significantly, both at baseline and post-synbiotic treatment. Synbiotic-related improvement in ICGR15 was significantly associated with changes in IL-6, both at mRNA and protein levels, and unrelated to plasma endotoxin values. No significant changes in any study parameter followed placebo treatment. Conclusions: Short-term synbiotic treatment proven to modulate gut flora significantly improves liver function in patients with cirrhosis. Benefit is unrelated to reduction in endotoxaemia and may be mediated, at least in part, by treatment-related induction of IL-6 synthesis by TNF-a.

[1]  Robert H Pierce,et al.  Paradoxical effects of short‐ and long‐term interleukin‐6 exposure on liver injury and repair , 2006, Hepatology.

[2]  C. De Simone,et al.  Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases , 2005, Journal of clinical gastroenterology.

[3]  D. Schuppan,et al.  Hepatocellular carcinomas do not compromise quantitative tests of liver function. , 2005, Hepato-gastroenterology.

[4]  M. Makuuchi,et al.  Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. , 2005, Journal of hepato-biliary-pancreatic surgery.

[5]  Heinz Steltzer,et al.  Comparison of invasive and noninvasive measurement of plasma disappearance rate of indocyanine green in patients undergoing liver transplantation: A prospective investigator‐blinded study , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  S. Riordan,et al.  Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis , 2004, Hepatology.

[7]  H. Tanabe,et al.  Ingestion of resistant starch protects endotoxin influx from the intestinal tract and reduces D‐galactosamine‐induced liver injury in rats , 2004, Journal of gastroenterology and hepatology.

[8]  Zhaoli Sun,et al.  In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. , 2003, Gastroenterology.

[9]  Roger Williams,et al.  Peripheral blood mononuclear cell expression of toll‐like receptors and relation to cytokine levels in cirrhosis , 2003, Hepatology.

[10]  M. Wheeler Endotoxin and Kupffer Cell Activation in Alcoholic Liver Disease , 2003, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.

[11]  N. Selzner,et al.  Cold ischemia decreases liver regeneration after partial liver transplantation in the rat: A TNF‐α/IL‐6–dependent mechanism , 2002, Hepatology.

[12]  T. Zimmers,et al.  Induction of Cachexia in Mice by Systemically Administered Myostatin , 2002, Science.

[13]  Z. Tian,et al.  Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-xL proteins , 2002, Oncogene.

[14]  G. Ciliberto,et al.  Interleukin-6 Protects against Fas-mediated Death by Establishing a Critical Level of Anti-apoptotic Hepatic Proteins FLIP, Bcl-2, and Bcl-xL* , 2001, The Journal of Biological Chemistry.

[15]  M. Febbraio,et al.  Carbohydrate ingestion attenuates the increase in plasma interleukin‐6, but not skeletal muscle interleukin‐6 mRNA, during exercise in humans , 2001, The Journal of physiology.

[16]  N. Enomoto,et al.  Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin. , 2001, Alcoholism, clinical and experimental research.

[17]  K. Reinhart,et al.  Comparison of invasive and noninvasive measurements of indocyanine green plasma disappearance rate in critically ill patients with mechanical ventilation and stable hemodynamics , 2000, Intensive Care Medicine.

[18]  D. Tweardy,et al.  Distinct effects of systemic infusion of G-CSF vs. IL-6 on lung and liver inflammation and injury in hemorrhagic shock. , 2000, Shock.

[19]  Gennaro Ciliberto,et al.  Increased toxin‐induced liver injury and fibrosis in interleukin‐6–deficient mice , 2000, Hepatology.

[20]  D. Brenner,et al.  Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. , 1998, Gastroenterology.

[21]  P. Rieckmann,et al.  Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. , 1997, Journal of immunological methods.

[22]  P. Clavien,et al.  Interleukin‐6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent , 1997, Hepatology.

[23]  P. Mandrekar,et al.  Alcohol-induced regulation of nuclear regulatory factor-kappa beta in human monocytes. , 1997, Alcoholism, clinical and experimental research.

[24]  E. Furth,et al.  Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice , 1996, Science.

[25]  H. Fujiwara,et al.  Critical involvement of interferon γ in the pathogenesis of T‐cell activation‐associated hepatitis and regulatory mechanisms of interleukin‐6 for the manifestations of hepatitis , 1996, Hepatology.

[26]  S. D. Lee,et al.  Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. , 1996, Scandinavian journal of gastroenterology.

[27]  D. Fuchs,et al.  Neopterin and soluble tumor necrosis factor receptor type I in alcohol‐induced cirrhosis , 1995, Hepatology.

[28]  H. Tilg,et al.  Circulating interleukin‐1 and tumor necrosis factor antagonists in liver disease , 1993, Hepatology.

[29]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.